Kaneh Bosm BioTechnology (CSE:KBB) announced the acquisition of portfolio company EU Cannabis which holds a license application process for medical cannabis in Greece.

As quoted in the press release:


EU Cannabis controls a 13-acre land package situated in Northern Greece, which upon receipt of the medicinal Cannabis licence will be dedicated to medical grade Cannabis cultivation, extraction, distribution, as well as research and development. In the coming days, EU Cannabis plans to commence the installation of fencing and security gates according to established best practice guidelines. While awaiting conditional approval from the Greek government, EU Cannabis will concurrently finalize an alarm, signage and security plan that is fully compliant with Greece’s current medical Cannabis regulatory environment.

Eugene Beukman, Chief Executive Officer of Kaneh Bosm states, “EU Cannabis affords Greece a turnkey service offering that will allow for the expedited development of a vertically integrated medical Cannabis facility. By leveraging access to capital, global connections and Cannabis expertise, EU Cannabis will act as a partner and advisor to the Greek government’s quest to establish a safe and sustainable medical Cannabis industry. EU Cannabis provides an unparalleled network of local partners and industry expertise necessary achieve a world-class Cannabis operation. EU Cannabis’ expanding cultivation capabilities will be complemented by Kaneh Bosm’s established distribution network of approximately 35,000 pharmacies throughout 16 countries”.

Upon receiving conditional approval from the appropriate Greek authorities, EU Cannabis plans to break ground on the construction of three separate structures with a total footprint of 97,000 square feet.

Click here to read the full press release.

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less